1. High volume
Low volume
HORRAD
STAMPEDE
Failure-free survival
Progression-free survival
HORRAD12
STAMPEDE11
Overall survival
Trial name
Outcome and
151/177
23/39
355/405
230/387
124/177
13/39
304/405
179/387
119/177
12/39
222/405
101/387
events/patients
RT+ADT
165/181
22/35
364/416
284/385
129/181
16/35
300/416
188/385
124/181
15/35
217/416
120/385
ADT
Favours .5 1 2
p=0.003
1.40 (1.12, 1.74)
1.10 (0.58, 2.09)
1.44 (1.14, 1.82)
p=0.054
1.28 (1.00, 1.64)
1.96 (0.88, 4.38)
1.22 (0.94, 1.59)
p=0.017
1.44 (1.07, 1.95)
1.98 (0.86, 4.53)
1.38 (1.00, 1.90)
HR (95% CI)
Interaction
100.00
11.60
88.40
9.63
90.37
13.21
86.79
Weight %
Greater treatment effect
with higher
Volume of disease
with lower
Supplementary Figure 2: (Exploratory) Effect of adding prostate radiotherapy to ADT on overall survival, progression-free survival and failure-free survival by volume of disease